Autoimmune Disease Therapeutics: Market Research Report

October 2011 | 749 pages | ID: AC883E0E9A9EN
Global Industry Analysts, Inc

Abstracts

This report analyzes the worldwide markets for Autoimmune Disease Therapeutics in US$ Million by the following Therapeutic Class: Rheumatoid Arthritis (Biologics), Multiple Sclerosis, Psoriasis, Crohn's Disease (Biologics), and Others.

The report provides separate comprehensive analytics for the US, Japan, Europe, and Rest of World.

Annual estimates and forecasts are provided for the period 2009 through 2017.

Also, a six-year historic analysis is provided for these markets.

The report profiles 112 companies including many key and niche players such as Abbott Laboratories, Amgen Inc., Bayer Schering Pharma AG, Biogen Idec Inc., Bristol-Myers Squibb Company, Elan Corporation, plc, Eli Lilly And Company, F.Hoffmann-la Roche AG, Chugai Pharmaceutical Co., Ltd., Genentech, Inc., GlaxoSmithKline plc, Johnson & Johnson, Inc., Merck & Co., Inc, Merck Serono SA, Novartis AG, Sanofi-aventis SA , Shire Plc, Teva Pharmaceuticals Industries Limited, and UCB S.A.

Market data and analytics are derived from primary and secondary research.

Company profiles are mostly extracted from URL research and reported select online sources.

Contents

1. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

Study Reliability and Reporting Limitations
Disclaimers
Data Interpretation & Reporting Level
Quantitative Techniques & Analytics
Product Definition and Scope of Study
Rheumatoid Arthritis
Multiple Sclerosis
Psoriasis
Crohn's disease

2. INDUSTRY OVERVIEW & OUTLOOK

Autoimmune Disease Therapeutics Market Continues to Flourish
Pharmaceutical Industry Hit by Economic Downturn
Economic Downturn Takes Toll on R&D
Current and Future Analysis
Segment Analysis
Rheumatoid Arthritis Therapeutics – The Largest Segment
Multiple Sclerosis Therapeutics Market
Crohn’s Disease Therapeutics Market
Ulcerative Colitis Drugs Market

3. MARKET DYNAMICS AND TRENDS

Biologics Find Acceptance as First Line of Treatment for Autoimmune Diseases
High Unmet Need Favors Growth
Impact of Biosimilars Legislation on Biologic Arthritis Drugs Market
New Products to Drive Market Growth
Biogenerics to Expand Adoption of Biological Drugs
Risk of Cancer Due to Anti-TNF Drugs
Superior Outcomes to Enhance Adoption of Biologics
Efficacy and Convenience – Key Factors Driving Physician’s Decision

4. DISEASE OVERVIEW

Immunity and Immune System
Autoimmune Diseases
Women- Highly Susceptible to Autoimmune Diseases

Table 1. Percentage Breakdown of Incidence of Autoimmune Diseases in Men and Women (includes corresponding Graph/Chart)

Complexity in Manifestations Renders Difficulty in Understanding the Conditions
Etiology of Autoimmune Diseases
Genetic Predisposition
Environmental Factors
Autoimmune Diseases – A Social and Health Burden
Regulatory Glitches and High Costs Hinder Biogenerics
Types of Autoimmune Diseases
Incidence and Prevalence
Diagnosis and Treatment of Autoimmune Diseases
Overview on Select Biologic Drugs
Remicade
Humira
Rituxan® (rituximab)
Cimzia
Cimzia to Face Stiff Competition in Rheumatoid Arthritis Market
Psoriasis – A Promising Market for Cimzia
Actemra
Enbrel

5. OVERVIEW OF SELECT AUTOIMMUNE DISEASES

Rheumatoid Arthritis
Disease Overview
Low Penetration to Sustain growth of Anti-TNF Drugs
Incidence and Prevalence Higher in Urban and Developed Regions
Symptoms and Diagnosis
Treatment of Rheumatoid Arthritis
BRMs Revolutionize RA Treatment
Branded Products
Drugs Used in Treating Rheumatoid Arthritis
Year of Approval of Leading Biologics in Rheumatoid Arthritis Therapy
Key Drugs in Late Stage Development for Rheumatoid Arthritis Treatment
Competitive landscape

Table 2. Comparative Analysis of Leading Biologic Rheumatoid Arthritis Drugs based on ACR Scores by End Point

High Prices and Safety Concerns
Multiple Sclerosis
Etiology
Types of Multiple Sclerosis

Table 3. Prevalence of Different Types of Multiple Sclerosis

Pathology
Prevalence of Multiple Sclerosis High in Women
Facts About Multiple Sclerosis
Treatment
Interferon Drugs - High Efficacy Drugs in Existing MS Therapies
Beta Interferon Drugs in Multiple Sclerosis Treatment
Non-Interferon Drugs
Non-Interferon Drugs in Multiple Sclerosis Treatment
Trends in Multiple Sclerosis Market
High Unmet Need and Rich Pipeline to Expand MS Market
Interferon-based Drugs Lead Multiple Sclerosis Drug Market
Oral Drugs Alter Dynamics in MS Therapies Market
Dip in Sales Inevitable for Current Therapies
Tough Times Ahead for Betaseron
Competitive landscape

Table 4. Leading Products/Companies in the Global Multiple Sclerosis Therapeutics Market (2010): Percentage Share Breakdown of Value Sales for Biogen Idec, Teva/sanofi-aventis*, Merck Serono, Bayer Schering, Elan, and Others (includes corresponding Graph/Chart)

Multiple Sclerosis Drug Pipeline – An Overview
Drugs Under Development for Treating Multiple Sclerosis
Fingolimod (Gilenya)
Mylinax
Laquinimod
Campath (Alemtuzumab)
Teriflunomide
Fampridine-SR
BG-12 (Oral Fumarate)
MN-166
Psoriasis
Prevalence
Available Treatment Options
Biological Drugs
Biological Drugs Lead the Fray
Potential Therapeutic Products
Inflammatory Bowel Diseases
Crohn's disease
Stages of the Disease
Prevalence
Diagnosis
Treatment
Ulcerative Colitis
Diagnosis and Treatment
Other Diseases
Systemic Lupus Erythematosus (SLE)
Prevalence and Epidemiology
Treatment
Sjogren's Syndrome
Prevalence and Epidemiology
Diagnosis and Treatment
Type-1 Diabetes Mellitus
Types of Diabetes Mellitus
Type 1 or Insulin Dependent Diabetes Mellitus
Type 2 or Non-Insulin Dependent Diabetes Mellitus
Insulin – Vital for Blood Glucose Management
Etiology
Prevalence
Diabetes in Children - A Growing Concern
Diagnosis and Treatment
Autoimmune Hepatitis
Disease Categories
Treatment
Side Effects
Juvenile Rheumatoid Arthritis
Symptoms
Diagnosis
Scleroderma
Prevalence
Etiology
Diagnosis
Management
Vasculitis Syndeomes
Haematologic Autoimmune Diseases
Ankylosing Spondylitis

6. CLINICAL TRIALS & RESEARCH STUDIES

Antares Pharma Commences VIBEX MTX Clinical Trial for Treating Rheumatoid Arthritis
Avila Therapeutics Introduces Btk Inhibitor for Treating Autoimmune Diseases and Cancer
Athersys and Angiotech to Conduct MultiStem® Clinical Trial
BioMarin Commences Amifampridine Phosphate Clinical Trial for Treating LEMS
TxCell Successfully Completes Trial for Crohn's Disease Cell Therapy
Novartis Releases Phase II Data for AIN457
Sanofi Releases Phase III TEMSO Study Results of Teriflunomide
Biogen Achieves Positive Results for BG-12 Drug Trial
Innate Therapeutics Commences MIS416 Clinical Trial in Progressive MS Patients
Pfizer Completes Clinical Trials for Tasocitinib
Compugen Completes Animal Model Study of CGEN-15001
Avila Therapeutics Commences AVL-292 Clinical Trial
Horizon Pharma Completes Clinical Trials for LODOTRA®
ChemoCentryx Begins Phase 1 Clinical trial for CCX168
NYU Langone Medical Center Announces Potential Therapy for Rheumatoid Arthritis
Compugen to Start Preclinical Development for Therapeutic Drugs
Avila Therapeutics Begins Phase I Clinical Trial for AVL-292
VBL Therapeutics Releases Preclinical Data for VB-201
GlaxoSmithKline and Dynavax Select DV1179 for Endosomal TLR Inhibitor Program
Idera Pharmaceuticals Starts Phase 1 Clinical Study of IMO-3100
ChemoCentryx Begins Phase I Clinical Study of CCX168
VBL Therapeutics Starts Phase II Clinical Study of VB-201
ChemoCentryx Begins Phase II Clinical Study of CCX354
Neovacs Starts Phase IIa Clinical Study of TNF Kinoid
Galapagos Begins Phase II Clinical Study of Nanocort
Plexxikon Starts Dosing of PLX3397 in Phase I Clinical Study

7. PRODUCT INTRODUCTIONS/APPROVALS

Horizon Pharma Receives FDA Approval for DUEXIS®
Venus Remedies to Launch Trois
CNRS/Inserm Researchers Introduce Dendrimer ABP as RA Therapy
Food and Drug Monitoring Agency to Approve Tocilizumab for Commercial Use
Novartis Bags EC Approval for Gilenya®
Genentech Obtains FDA Approval for ACTEMRA
Novartis Gains Approval for Gilenya in Japan
Novartis Receives FDA Approval for Gilenya
Compugen Discovers and Validates CGEN-15001 Soluble Recombinant Fusion Protein
InNexus Biotechnology Develops IXSCD11a
Centocor Ortho Biotech Submits sBLA for Simponi Label Extension
Osiris Therapeutics Obtains Orphan Drug Designation for Prochymal from FDA
Immunomedics Obtains US Patent for Immunotherapy
Biogen Idec Introduces Monoclonal Antibody Tysabri in India
Merck Serono Unveils Pre-Filled Pen RebiDose™ in UK
BioMarin Unveils Firdapse™ in European Union
Sandoz Introduces Calcipotriene Solution in US
Cimzia® Receives FDA Approval for Treating Rheumatoid Arthritis
Simponi™ Receives FDA Approval for Treating Rheumatoid Arthritis
Novartis Introduces Extavia® for Multiple Sclerosis Treatment in Denmark & Germany
Novartis Bags FDA Approval for Extavia
UCB Receives EC Approval for Cimzia
Centocor Ortho Biotech Receives FDA Approval for Stelara
BioMarin Pharmaceutical Bags FDA’s Orphan Drug Designation
Promius Pharma Introduces Scytera™ for Psoriasis Treatment
Galderma Receives FDA Approval for Plaque Psoriasis Ointment Vectical™
Roche Obtains EC Approval for Rheumatoid Arthritis Antibody RoACTEMRA
Viron Therapeutics Obtains US Patents for VT-384, VT-346 Candidates
Bayer Schering Pharma Obtains Approval for Betafron® Therapy from SFDA
US Food and Drug Administration Approves Certolizumab Pegol
Nitec Unveils Lodotra® in Germany

8. PRODUCT INNOVATIONS/INTRODUCTIONS IN THE RECENT PAST – A PERSPECTIVE BUILDER

HUMIRA® Obtains EU Approval for Polyarticular Juvenile Idiopathic Arthritis
Cimzia® Receives FDA Nod for Treating Crohn’s Disease
HUMIRA® Obtains Approval from Japanese Ministry for Rheumatoid Arthritis
HUMIRA® Receives FDA Clerance for Polyarticular Juvenile Idiopathic Arthritis
Abbott Receives EU Marketing Authorization for Humira in Psoriasis Treatment
Xian-Janssen Introduces Remicade, Branded infliximab in China
HUMIRA® Obtains EU Approval for Treating Crohn’s Disease
HUMIRA® Obtains FDA Approval for Crohn’s Disease
Remicade® Obtains Approval for Use in PsA and Early RA in Australia
Tysabri™ Receives Health Canada Approval for Use in Multiple Sclerosis
Rituxan® Gets FDA Approval for Use in RA
Humira® Obtains FDA Approval for Treating AS
Betaseron® Receives FDA Approval for Use in First Clinical Episode of MS
Abbott Receives FDA Clearance for HUMIRA Pen
Remicade Obtains FDA Approval for Treating Pediatric Crohn`s Disease

9. RECENT INDUSTRY ACTIVITY

Sanofi-Aventis Takes over Genzyme
Daiichi Sankyo to Acquire Plexxikon
TiGenix Takes Over Cellerix
Alkermes and Elan Drug Technologies to Merge Operations
Pfizer Japan Inks Agreements with Takeda to Co-Promote RA Drugs
Viropro Inks Letter of Agreement with Spectrum Pharmaceuticals
Pepscan Therapeutics Collaborates with Phylogica
Lycera Enters into Research Collaboration with Merck
Merck Amends Distribution Agreement with Johnson & Johnson
Yale University and Debiopharm Enter into License Agreement for Debio 1036
Opexa Therapeutics Inks Agreement with American Red Cross
Antitope and NasVax Enter into Research Collaboration
SuppreMol Inks In-License Agreement with Bayerische Patentallianz
Glenmark Inks License Agreement with Sanofi
Exagen Enters into Partnership with Medco
Phylogica Inks Research Collaboration and Option Agreement with Pepscan Therapeutics
Merck Sharp & Dohme Enters into Partnership with Lycera
Amgen Enters into Collaboration with Xencor
PhRMA Announces Development of Medicines Targeted Towards Women
Circassia Secures Global Development and Marketing Rights to PAP-1 from Airmid
UCB Establishes Microbial Production Facility
Emergent BioSolutions Takes Over Trubion Pharmaceuticals
Gilead Sciences to Takeover CGI Pharmaceuticals
Abbott Laboratories Acquires Facet Biotech
Merck Takes Over Millipore
Quidel to Snap Up Diagnostic Hybrids
Nitec Pharma Merges with Horizon Therapeutics
Femta Pharmaceuticals Inks Manufacturing Agreement with Lonza Group
Horizon Pharma Signs Agreement with Mundipharma International
3SBIO SIGNS AGREEMENT WITH ISOTECHNIKA PHARMA
Fast Forward and Provid Pharmaceuticals Extend Partnership
Antitope and PIKAMAB Collaborate
Ligon Discovery Enters into Agreement with Lycera
Axxam, Fast Forward and Juvenile Diabetes Research Foundation Enter into Partnership
GlaxoSmithKline Collaborates with ChemoCentryx
Perseid Signs Agreement with Astellas Pharma for CTLA4-Ig Program
Cellceutix Chooses Destum Partners for KM-133 Psoriasis Compound
NERC Commences Operations of IXO Therapeutics
Avesthagen to Market Avent
Isotechnika Pharma Divests Stake in Isodiagnostika
MacroGenics Obtains New Grants from NIH
AnaptysBio Collaborates with VLST to Generate Novel Antibody Therapeutics
AstraZeneca Enters into Exclusive License Agreement with Rigel Pharmaceuticals
Immutep Inks License Agreement with GlaxoSmithKline for Therapeutic Antibody IMP731
Novo Nordisk Inks Research Collaboration Agreement with Combine
Xention and Axxam Enter into Autoimmune Disorder Research Partnership
Roche Takes Over Genentech
Merck Acquires Schering-Plough
Pfizer Takes Over Wyeth
Amgen Takes Over Immunex
BioMarin Pharmaceutical Takes Over Huxley Pharmaceuticals
Onyx to Takeover Proteolix
Genzyme Takes Over Global Rights of Campath, Leukine and Fludara from Bayer
Bristol-Myers Squibb Enters into Agreement with Alder Biopharmaceuticals
LEO Pharma Inks Agreement with Warner Chilcott
Kineta One Acquires Commercial Rights for Compounds from Airmid
Kineta Signs Agreement with Alturas Analytics
Catalyst Biosciences in Research and License Agreement with MedImmune
Boehringer Ingelheimes Collaborates with Exelixis
Lonza Signs Agreement with Opsona Therapeutics for Manufacturing Antibody
Eli Lilly and Incyte Enter into Agreement
Novartis Option Fund and Avila Therapeutics Sign Option Agreement
Genentech Acquires Rights for BHT-3021 from Bayhill Therapeutics
Celentyx and Meiji Seika Kaisha Ink Agreement
Exelixis and Boehringer Ingelheim Enter into Autoimmune Disease Partnership
Celldex Acquires Exclusive Rights of Immune-Stimulatory Molecules from Amgen
Apitope and Merck Serono Sign Agreement for Multiple Sclerosis Drug
Biovitrum and Affibody® Enter into Collaboration
Bayhill Therapeutics Bags Contract from Genentech

10. CORPORATE ACTIVITY IN THE RECENT PAST – A PERSPECTIVE BUILDER

Novo Nordisk and VLST Collaborate on Therapeutic Targets Development
Actemra’s Approval Gets Delayed
Apitope Raises Financing for Developing Multiple Sclerosis Compound
CalciMedica to Acquire Rights to STIM1 from TorreyPines
Roche Acquires ARIUS Research, Inc.
Astellas Inks Agreement with Maxygen for MAXY-4 Candidates
Carna and Caliper Life Sciences Ink Collaborative Supply Agreement
Isotechnika Gets Back Worldwide Rights to Transplant Drug, Voclosporin
Boehringer In-licenses Two Drug Targets from BioFocus
Bionomics Enters into a Development and Licensing Agreement with Merck Serono
Nycomed Inks Agreement with Immunomedics for Veltuzumab
EpiVax Receives Grants from National Institutes of Health to Advance Epi-13
Boehringer to Takeover Actimis
Antisoma Acquires Xanthus Pharmaceuticals
Merrimack Acquires Funds for Developing Cancer and Autoimmune Disease Biologics
BioSeek and Merck Sign Collaboration Agreement for Compound Evaluation
Questcor Amends Distribution Contract with US Distributor of Acthar
ANP Completes Phase IIa Trial for Multiple Sclerosis Drug
Insert and Calando Merge to Form Calando Pharmaceuticals
Codon Inks Research & Development and Licensing Deal with Merrimack
Debiopharm Inks licensing Deal with Airmid for Debio 0824 ShK Peptide
Chelsea Acquires Global Rights to I-3D Range of DHODH Inhibiting Compounds
Cypress Bioscience Acquires Proprius
J&J PRD Grants Milestone Payment to Sunesis Pharmaceuticals
GlaxoSmithKline Acquires License to Market Vaccinex’s Antibody
Teva to Takeover CoGenesys
Hadasit, HMS and BWH to Co-develop Oral Therapy for Autoimmune Diseases
Anthera Acquires Rights to Develop and Market AMG 623 from Amgen
Can-Fite Enters into Two Cooperation Agreements to Develop CF102 Drug
Source MDx Inks an Agreement with Pfizer
Cambridge Inks an Antibody Development Agreement with Medarex
Pfizer to Acquire Coley Pharma
GSK Joins Hands with Tolerx to Develop and Commercialize otelixizumab
Amgen Acquires Avidia
Eli Lilly and MacroGenics Tie Up for Developing Teplizumab
MorphoSys and Genesis Ink Antibody R&D Deal
arGentis Enters into a License Agreement with UTRF
Eden Biodesign to Investigate Novel Drug Candidate for Autoimmune Diseases
Nuon and Kissei Team up for Tranilast
Organon and Dyax Team Up for Developing Therapeutic Antibodies
Medarex Joins Hands with Mitsubishi for Monoclonal Antibody Development
Merck and Archemix Collaborate
Genzyme Takes Over Bioenvision
Organon and Medarex Ink Drug Development Deal
CalciMedica Secures Exclusive Rights for CBR’s Autoimmune Drug Target
Xanthus Secures Exclusive Patent Estate Rights for FLT3 Pathway
Eisai Corporation Acquires Morphotek
TIRC Changes Name to Orchestra Therapeutics
Abbott Files HUMIRA® for Psoriasis in the US and EU (USA/Europe)
Accentia Secures Exclusive Global Rights to Revimmune
Medarex and Compugen Ink Collaborative Agreement for Therapeutic Antibody
SRI and Telik Sign License Agreement for Drug Development
China Biopharma Signs Agreement with Chinese Biopharmaceutical Firm
Kirin and Astellas Ink Licensing Agreement for Anti-CD40 Antagonistic mAb
QSV and Artielle Sign Contract to Produce RTL-1000
JDRF and MacroGenics Form Partnership
GSK and Genmad Sign Partnership Agreement for HuMaxCD20
Biocon Enters into Joint Venture Agreement with Neopharma
Pipex Pharmaceuticals Acquires Remaining Stake in Effective Pharmaceuticals
Astellas Acquires Worldwide Rights for Amevive®
Biogen Acquires Fumapharm
Biogen and UCB Join Hands for Oral Multiple Sclerosis Therapy

11. FOCUS ON SELECT GLOBAL PLAYERS

Abbott Laboratories (USA)
Amgen Inc. (USA)
Bayer Schering Pharma AG (Germany)
Biogen Idec Inc. (USA)
Bristol-Myers Squibb Company (USA)
Elan Corporation plc (Ireland)
Eli Lilly and Company (USA)
F. Hoffmann-La Roche AG (Switzerland)
Chugai Pharmaceutical Co. , Ltd. (Japan)
Genentech, Inc. (USA)
GlaxoSmithKline Plc (UK)
Johnson & Johnson, Inc. (USA)
Merck & Co. , Inc. (US)
Merck Serono SA (Switzerland)
Novartis AG (Switzerland)
Sanofi-aventis SA (France)
Shire Plc (Ireland)
Teva Pharmaceuticals Industries Limited (Israel)
UCB S. A. (Belgium)

12. GLOBAL MARKET PERSPECTIVE

Table 5. World Recent Past, Current & Future Analysis for Autoimmune Disease Therapeutics by Geographic Region – US, Japan, Europe and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)

Table 6. World Historic Review for Autoimmune Disease Therapeutics by Geographic Region – US, Japan, Europe and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)

Table 7. World 15-year Perspective for Autoimmune Disease Therapeutics by Geographic Region – Percentage Breakdown of Dollar Sales for US, Japan, Europe and Rest of World Markets for Years 2003, 2010 & 2017 (includes corresponding Graph/Chart)

Table 8. World Recent Past, Current & Future Analysis for Rheumatoid Arthritis Therapeutics (Biologics) by Geographic Region – US, Japan, Europe and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)

Table 9. World Historic Review for Rheumatoid Arthritis Therapeutics (Biologics) by Geographic Region – US, Japan, Europe and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)

Table 10. World 15-year Perspective for Rheumatoid Arthritis Therapeutics (Biologics) by Geographic Region – Percentage Breakdown of Dollar Sales for US, Japan, Europe and Rest of World Markets for Years 2003, 2010 & 2017 (includes corresponding Graph/Chart)

Table 11. World Recent Past, Current & Future Analysis for Multiple Sclerosis Therapeutics by Geographic Region – US, Japan, Europe and Rest of World- Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)

Table 12. World Historic Review for Multiple Sclerosis Therapeutics by Geographic Region – US, Japan, Europe and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)

Table 13. World 15-year Perspective for Multiple Sclerosis Therapeutics by Geographic Region – Percentage Breakdown of Dollar Sales for US, Japan, Europe and Rest of World Markets for Years 2003, 2010 & 2017 (includes corresponding Graph/Chart)

Table 14. World Recent Past, Current & Future Analysis for Psoriasis Therapeutics by Geographic Region – US, Japan, Europe and Rest of World- Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)

Table 15. World Historic Review for Psoriasis Therapeutics by Geographic Region – US, Japan, Europe and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)

Table 16. World 15-year Perspective for Psoriasis Therapeutics by Geographic Region – Percentage Breakdown of Dollar Sales for US, Japan, Europe and Rest of World Markets for Years 2003, 2010 & 2017 (includes corresponding Graph/Chart)

Table 17. World Recent Past, Current & Future Analysis for Crohn’s Disease Therapeutics (Biologicals) by Geographic Region – US, Japan, Europe and Rest of World- Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)

Table 18. World Historic Review for Crohn’s Disease Therapeutics (Biologicals) by Geographic Region – US, Japan, Europe and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)

Table 19. World 15-year Perspective for Crohn’s Disease Therapeutics (Biologicals) by Geographic Region – Percentage Breakdown of Dollar Sales for US, Japan, Europe and Rest of World Markets for Years 2003, 2010 & 2017 (includes corresponding Graph/Chart)

Table 20. World Recent Past, Current & Future Analysis for Other Autoimmune Disease Therapeutics by Geographic Region – US, Japan, Europe and Rest of World- Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)

Table 21. World Historic Review for Other Autoimmune Disease Therapeutics by Geographic Region – US, Japan, Europe and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)

Table 22. World 15-year Perspective for Other Autoimmune Disease Therapeutics by Geographic Region – Percentage Breakdown of Dollar Sales for US, Japan, Europe and Rest of World Markets for Years 2003, 2010 & 2017 (includes corresponding Graph/Chart)

13. THE UNITED STATES

A. MARKET ANALYSIS

Current and Future Analysis
Autoimmune Diseases Fact Sheet

Table 23. Prevalence of Key Autoimmune Diseases in the US (in Millions) (includes corresponding Graph/Chart)

Market Trends
Biologic Drugs Lead the Fray
Biologics To Add Further Impetus to the Market
Rheumatoid Arthritis Drugs Lead the Market
Enbrel and Humira Continue to Gain Share in the Anti-TNF Market
Increased Incidence and Rise in Drug Prices to Drive Growth in MS Market

Table 24. Leading Multiple Sclerosis Drugs in the US (2008): Percentage Share Breakdown of New Prescriptions Written for Avonex, Copaxone, Rebif, Betaseron, and Tysabri (includes corresponding Graph/Chart)

Incidence of Type 1 Diabetes Mellitus Endemic in White Youth
Lialda’s Share Gaining Momentum in Ulcerative Colitis Drugs Market
Key Ulcerative Colitis Drugs Market in the US (2006)
Product Launches/Approvals
Strategic Corporate Developments
Key Players

B. MARKET ANALYTICS

Table 25. US Recent Past, Current & Future Analysis for Autoimmune Disease Therapeutics by Disease Segment – Rheumatoid Arthritis (Biologics), Multiple Sclerosis, Psoriasis, Crohn’s Disease (Biologics) and Other Autoimmune Diseases Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)

Table 26. US Historic Review for Autoimmune Disease Therapeutics by Disease Segment – Rheumatoid Arthritis (Biologics), Multiple Sclerosis, Psoriasis, Crohn’s Disease (Biologics) and Other Autoimmune Diseases Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)

Table 27. US 15-Year Perspective for Autoimmune Disease Therapeutics by Disease Segment – Percentage Breakdown of Dollar Sales for Rheumatoid Arthritis (Biologics), Multiple Sclerosis, Psoriasis, Crohn’s Disease (Biologics) and Other Autoimmune Diseases for Years 2003, 2010 & 2017 (includes corresponding Graph/Chart)

14. JAPAN

A. MARKET ANALYSIS

Current and Future Analysis
Japanese Patients Exhibit Unique Efficacy & Safety Effects
Product Launches/Approvals
Strategic Corporate Developments
Key Players

B. MARKET ANALYTICS

Table 28. Japanese Recent Past, Current & Future Analysis for Autoimmune Disease Therapeutics by Disease Segment – Rheumatoid Arthritis (Biologics), Multiple Sclerosis, Psoriasis, Crohn’s Disease (Biologics) and Other Autoimmune Diseases Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)

Table 29. Japanese Historic Review for Autoimmune Disease Therapeutics by Disease Segment – Rheumatoid Arthritis (Biologics), Multiple Sclerosis, Psoriasis, Crohn’s Disease (Biologics) and Other Autoimmune Diseases Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)

Table 30. Japanese 15-Year Perspective for Autoimmune Disease Therapeutics by Disease Segment – Percentage Breakdown of Dollar Sales for Rheumatoid Arthritis (Biologics), Multiple Sclerosis, Psoriasis, Crohn’s Disease (Biologics) and Other Autoimmune Diseases for Years 2003, 2010 & 2017 (includes corresponding Graph/Chart)

15. EUROPE

A. MARKET ANALYSIS

Current and Future Analysis
Europe – A Burgeoning Market for Autoimmune Disease Therapeutics
Increasing Awareness to Drive Market Growth
Low Penetration to Fuel Growth in European MS DMDs Market

Table 31. Prevalence of Key Autoimmune Diseases in Europe in Millions (includes corresponding Graph/Chart)

Lower Treatment Rate Bodes Huge Potential for the UK MS Drug Market
Drugs Hindering Disease Progression to Gain Prominence
Rising Demand for Rheumatoid Arthritis Drugs in Russia
Product Launches/Approvals
Strategic Corporate Developments
Key Players

B. MARKET ANALYTICS

Table 32. European Recent Past, Current & Future Analysis for Autoimmune Disease Therapeutics by Disease Segment – Rheumatoid Arthritis (Biologics), Multiple Sclerosis, Psoriasis, Crohn’s Disease (Biologics) and Other Autoimmune Diseases Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)

Table 33. European Historic Review for Autoimmune Disease Therapeutics by Disease Segment – Rheumatoid Arthritis (Biologics), Multiple Sclerosis, Psoriasis, Crohn’s Disease (Biologics) and Other Autoimmune Diseases Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)

Table 34. European 15-Year Perspective for Autoimmune Disease Therapeutics by Disease Segment – Percentage Breakdown of Dollar Sales for Rheumatoid Arthritis (Biologics), Multiple Sclerosis, Psoriasis, Crohn’s Disease (Biologics), and Other Autoimmune Diseases for Years 2003, 2010 & 2017 (includes corresponding Graph/Chart)

16. REST OF WORLD

A. MARKET ANALYSIS

Current and Future Analysis
Canada
Canada – Highest Prevalence Rates for Multiple Sclerosis
Sales of Biologics on the Rise in Canadian Rheumatoid Arthritis Drugs Market
Asia-Pacific
Autoimmune Diseases Market in Asia-Pacific – An Overview
Incidence of Multiple Sclerosis in India on the Rise
Overview of Rheumatoid Arthritis in Australia

Table 35. Percentage Breakdown of Prevalence of Rheumatoid Arthritis in Australia by Age Group (includes corresponding Graph/Chart)

Table 36. Percentage Breakdown of Prevalence of Rheumatoid Arthritis in Australia by Sex (includes corresponding Graph/Chart)

Overview of Irritable Bowel Diseases in Australia
Product Launches/Approvals
Strategic Corporate Developments
Key Player

B. MARKET ANALYTICS

Table 37. Rest of World Recent Past, Current & Future Analysis for Autoimmune Disease Therapeutics by Disease Segment – Rheumatoid Arthritis (Biologics), Multiple Sclerosis, Psoriasis, Crohn’s Disease (Biologics) and Other Autoimmune Diseases Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)

Table 38. Rest of world Historic Review for Autoimmune Disease Therapeutics by Disease Segment – Rheumatoid Arthritis (Biologics), Multiple Sclerosis, Psoriasis, Crohn’s Disease (Biologics) and Other Autoimmune Diseases Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)

Table 39. Rest of World 15-Year Perspective for Autoimmune Disease Therapeutics by Disease Segment – Percentage Breakdown of Dollar Sales for Rheumatoid Arthritis (Biologics), Multiple Sclerosis, Psoriasis, Crohn’s Disease (Biologics) and Other Autoimmune Diseases for Years 2003, 2010 & 2017 (includes corresponding Graph/Chart)

Total Companies Profiled: 112 (including Divisions/Subsidiaries - 124)
Region/CountryPlayers
The United States77
Canada
Japan
Europe
France
Germany
The United Kingdom
Rest of Europe
Asia-Pacific (Excluding Japan)
Middle East